Santa Ana Bio Raises $168M inSeries A and B Funding to Advance Precision Medicines for Inflammatory Illneses - Next Digital Health

A California-based precision immunology company, Santa Ana Bio, has emerged from stealth with a combined series A and B funding of $168 to deliver precision medicines for patients struggling with inflammatory diseases. According to the company’s announcement, the combined capital raised comprised $43 million in a Series A funding round led by Versant Ventures and Santa Ana Bio's latest capital infusion will help the company to advance precision medicines through 3 major programs ahead of clinical entry in 2025.
read more..